Philip J Rosenfeld

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. ncbi request reprint Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, Miami, Florida 33136, USA
    Ophthalmology 113:623.e1. 2006
  2. ncbi request reprint Verteporfin therapy of subfoveal occult choroidal neovascularization in AMD using delayed light application: one-year results of the VALIO Study
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Miami, FL, USA
    Am J Ophthalmol 144:970-972. 2007
  3. ncbi request reprint Ranibizumab: Phase III clinical trial results
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, 900 NW 17th Street, Miami, FL 33136, USA
    Ophthalmol Clin North Am 19:361-72. 2006
  4. ncbi request reprint Ranibizumab for neovascular age-related macular degeneration
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    N Engl J Med 355:1419-31. 2006
  5. doi request reprint Cataract surgery in ranibizumab-treated patients with neovascular age-related macular degeneration from the phase 3 ANCHOR and MARINA trials
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Am J Ophthalmol 152:793-8. 2011
  6. doi request reprint Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Ophthalmology 118:523-30. 2011
  7. ncbi request reprint Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami School of Medicine, Miami, FL 33136, USA
    Ophthalmology 111:1725-33. 2004
  8. ncbi request reprint Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration
    Philip J Rosenfeld
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miami, Florida 33136, USA
    Ophthalmology 112:1048-53. 2005
  9. doi request reprint A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study
    Geeta A Lalwani
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Am J Ophthalmol 148:43-58.e1. 2009
  10. doi request reprint Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion
    Ninel Z Gregori
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 NW 17th St, Miami, FL 33136, USA
    Retina 28:1325-37. 2008

Collaborators

Detail Information

Publications67

  1. ncbi request reprint Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, Miami, Florida 33136, USA
    Ophthalmology 113:623.e1. 2006
    ....
  2. ncbi request reprint Verteporfin therapy of subfoveal occult choroidal neovascularization in AMD using delayed light application: one-year results of the VALIO Study
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Miami, FL, USA
    Am J Ophthalmol 144:970-972. 2007
    ..To compare photodynamic therapy (PDT) with verteporfin (Visudyne; Novartis Pharma AG, Basel, Switzerland) using either standard or delayed light application...
  3. ncbi request reprint Ranibizumab: Phase III clinical trial results
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, 900 NW 17th Street, Miami, FL 33136, USA
    Ophthalmol Clin North Am 19:361-72. 2006
    ..At that time, the major dilemma facing most retina specialists will be whether to use intravitreal ranibizumab or intravitreal bevacizumab, the low cost alternative, for the treatment of neovascular AMD...
  4. ncbi request reprint Ranibizumab for neovascular age-related macular degeneration
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    N Engl J Med 355:1419-31. 2006
    ..Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration...
  5. doi request reprint Cataract surgery in ranibizumab-treated patients with neovascular age-related macular degeneration from the phase 3 ANCHOR and MARINA trials
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Am J Ophthalmol 152:793-8. 2011
    ....
  6. doi request reprint Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Ophthalmology 118:523-30. 2011
    ..To investigate the cause of visual acuity (VA) loss in patients with neovascular age-related macular degeneration (AMD) receiving monthly ranibizumab injections in the pivotal ranibizumab phase III trials...
  7. ncbi request reprint Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami School of Medicine, Miami, FL 33136, USA
    Ophthalmology 111:1725-33. 2004
    ....
  8. ncbi request reprint Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration
    Philip J Rosenfeld
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miami, Florida 33136, USA
    Ophthalmology 112:1048-53. 2005
    ..To investigate the maximum tolerated dose of ranibizumab administered as a single intravitreal injection...
  9. doi request reprint A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study
    Geeta A Lalwani
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Am J Ophthalmol 148:43-58.e1. 2009
    ....
  10. doi request reprint Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion
    Ninel Z Gregori
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 NW 17th St, Miami, FL 33136, USA
    Retina 28:1325-37. 2008
    ..To evaluate the long-term safety and efficacy of intravitreal bevacizumab injections (Avastin, Genentech Inc., San Francisco, CA) for the treatment of macular edema secondary to central retinal vein occlusions...
  11. ncbi request reprint Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
    Ryan M Rich
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami School of Medicine, FL 33136, USA
    Retina 26:495-511. 2006
    ..To evaluate the safety and efficacy of intravitreal bevacizumab (Avastin, Genentech Inc.) for the treatment of neovascular age-related macular degeneration (ARMD)...
  12. ncbi request reprint Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study
    Andrew A Moshfeghi
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Ophthalmology 113:2002.e1-12. 2006
    ..To evaluate the safety, efficacy, and durability of bevacizumab for the treatment of subfoveal choroidal neovascularization (CNV) in patients with neovascular age-related macular degeneration (AMD)...
  13. doi request reprint Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion
    Ninel Z Gregori
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Retina 29:913-25. 2009
    ..To evaluate the safety and efficacy of intravitreal bevacizumab (Avastin, Genentech) for the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO) and hemiretinal vein occlusion (HRVO)...
  14. ncbi request reprint One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion
    Ninel Z Gregori
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Retina 26:889-95. 2006
    ..To evaluate the safety and efficacy of intravitreal triamcinolone acetonide (IVTA) as treatment for macular edema associated with central retinal vein occlusion (CRVO)...
  15. ncbi request reprint Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center
    Andrew A Moshfeghi
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida 33418, USA
    Retina 31:662-8. 2011
    ....
  16. pmc Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study
    Zohar Yehoshua
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
    Ophthalmology 121:693-701. 2014
    ..To evaluate the effect of eculizumab, a systemic inhibitor of complement component (C5), on the growth of geographic atrophy (GA) in patients with age-related macular degeneration (AMD)...
  17. doi request reprint Quantitative imaging of retinal pigment epithelial detachments using spectral-domain optical coherence tomography
    Fernando M Penha
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Florida, USA
    Am J Ophthalmol 153:515-23. 2012
    ....
  18. ncbi request reprint Spectral domain optical coherence tomographic imaging of geographic atrophy
    Brandon J Lujan
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Ophthalmic Surg Lasers Imaging 40:96-101. 2009
    ..To compare images of geographic atrophy (GA) obtained using spectral domain optical coherence tomography (SD-OCT) with images obtained using fundus autofluorescence (FAF)...
  19. doi request reprint Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration
    Kimberly E Stepien
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida 33136, USA
    Retina 29:1067-73. 2009
    ..To compare outcomes after switching from intravitreal bevacizumab (Avastin) to ranibizumab (Lucentis) in patients with neovascular age-related macular degeneration (AMD)...
  20. pmc Spectral domain optical coherence tomography imaging of drusen in nonexudative age-related macular degeneration
    Giovanni Gregori
    Bascom Palmer Eye Institute, Miami, FL, USA
    Ophthalmology 118:1373-9. 2011
    ..To measure drusen area and volume in eyes with nonexudative age-related macular degeneration (AMD) using spectral domain optical coherence tomography imaging (SD-OCT)...
  21. ncbi request reprint Quantitative changes in retinal pigment epithelial detachments as a predictor for retreatment with anti-VEGF therapy
    Fernando M Penha
    Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, Florida 33136, USA
    Retina 33:459-66. 2013
    ....
  22. doi request reprint Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye)
    Michael W Stewart
    Department of Ophthalmology, Mayo Clinic College of Medicine, Jacksonville, Florida 32224, USA
    Retina 32:434-57. 2012
    ..Pharmacokinetic modeling was performed to determine if more frequent dosing with anti-VEGF drugs could be theoretically beneficial...
  23. ncbi request reprint Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami School of Medicine, Miami, Florida, USA
    Ophthalmic Surg Lasers Imaging 36:331-5. 2005
    ..An intravitreal injection of bevacizumab may provide an effective, safe, and inexpensive option for patients with age-related macular degeneration who are losing vision secondary to macular neovascularization...
  24. ncbi request reprint Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami School of Medicine, Miami, Florida, USA
    Ophthalmic Surg Lasers Imaging 36:336-9. 2005
    ..The improvements were maintained for at least 4 weeks. Intravitreal injections of bevacizumab may provide another treatment option for patients with macular edema from vein occlusions...
  25. doi request reprint Predicting the progression of geographic atrophy in age-related macular degeneration with SD-OCT en face imaging of the outer retina
    Renata Portella Nunes
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miller School of Medicine, Miami, Florida 33136, USA
    Ophthalmic Surg Lasers Imaging Retina 44:344-59. 2013
    ....
  26. ncbi request reprint Antiangiogenic therapy in neovascular age-related macular degeneration
    Richard C Lin
    Bascom Palmer Eye Institute, University of Miami School of Medicine, 900 NW 17th Street, Miami, FL 33136, USA
    Int Ophthalmol Clin 47:117-37. 2007
  27. pmc Natural history of drusen morphology in age-related macular degeneration using spectral domain optical coherence tomography
    Zohar Yehoshua
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Ophthalmology 118:2434-41. 2011
    ..To characterize the natural history of drusen using spectral-domain optical coherence tomography (SD-OCT) imaging of eyes from patients with nonexudative age-related macular degeneration (AMD)...
  28. doi request reprint Comparison of geographic atrophy measurements from the OCT fundus image and the sub-RPE slab image
    Zohar Yehoshua
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Ophthalmic Surg Lasers Imaging Retina 44:127-32. 2013
    ..To compare two different approaches to measuring areas of geographic atrophy (GA) using spectral-domain optical coherence tomography (SD-OCT)...
  29. doi request reprint Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy
    Gary Shienbaum
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA
    Am J Ophthalmol 155:1009-13. 2013
    ..To report the visual and anatomic outcomes of anti-vascular endothelial growth factor (VEGF) monotherapy in the management of marked submacular hemorrhage secondary to neovascular age-related macular degeneration (AMD)...
  30. pmc Comparison of drusen area detected by spectral domain optical coherence tomography and color fundus imaging
    Zohar Yehoshua
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Invest Ophthalmol Vis Sci 54:2429-34. 2013
    ....
  31. pmc Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography
    Zohar Yehoshua
    Bascom Palmer Eye Institute, Department of Ophthalmology, Universityof Miami Miller School of Medicine, Miami, Florida, USA
    Ophthalmology 118:679-86. 2011
    ..To determine the area and enlargement rate (ER) of geographic atrophy (GA) in patients with age-related macular degeneration (AMD) using the spectral domain optical coherence tomography (SD-OCT) fundus image...
  32. pmc Registration of OCT fundus images with color fundus photographs based on blood vessel ridges
    Ying Li
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Opt Express 19:7-16. 2011
    ..The average root mean square errors for the affine model are 31 µm (normal) and 59 µm (eyes with disease). The proposed algorithm can be easily adapted to registration for other modality retinal images...
  33. ncbi request reprint Imaging serpiginous choroidopathy with spectral domain optical coherence tomography
    Omar S Punjabi
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA
    Ophthalmic Surg Lasers Imaging 39:S95-8. 2008
    ..The researchers concluded that SD-OCT is a useful tool to study disease morphology and follow-up of chronic serpiginous choroiditis...
  34. doi request reprint Spectral domain optical coherence tomography characteristics of cuticular drusen
    Theodore Leng
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Retina 29:988-93. 2009
    ..To evaluate the appearance of cuticular drusen with spectral domain optical coherence tomography...
  35. ncbi request reprint Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study
    Stephan Michels
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida 33136, USA
    Ophthalmology 112:1035-47. 2005
    ..South San Francisco, CA) and its effects on visual acuity (VA) and subfoveal choroidal neovascularization (CNV) in patients with neovascular age-related macular degeneration (AMD)...
  36. doi request reprint Spectral-domain optical coherence tomography imaging of drusenoid pigment epithelial detachments
    Carlos Alexandre de Amorim Garcia Filho
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA
    Retina 33:1558-66. 2013
    ..To evaluate drusenoid retinal pigment epithelial detachments (DPED) secondary to age-related macular degeneration (AMD) using spectral-domain optical coherence tomography imaging...
  37. ncbi request reprint Identifying the boundaries of retinal pigment epithelial detachments using two spectral-domain optical coherence tomography instruments
    Fernando M Penha
    Bascom Palmer Eye Institute, 900 NW 17th St, Miami, FL 33136, USA
    Ophthalmic Surg Lasers Imaging Retina 44:10-6. 2013
    ..To compare two spectral-domain optical coherence tomography (SD-OCT) instruments in identifying the boundaries of retinal pigment epithelium detachment (PED)...
  38. doi request reprint Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II
    Jaclyn L Kovach
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA
    Retina 29:27-32. 2009
    ....
  39. doi request reprint Automated detection of the foveal center improves SD-OCT measurements of central retinal thickness
    Fenghua Wang
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Ophthalmic Surg Lasers Imaging 43:S32-7. 2012
    ..To investigate the performance of an automated foveal center detection algorithm on spectral-domain optical coherence tomography (SD-OCT)...
  40. doi request reprint Increasing volume of a retinal pigmented epithelial detachment as a predictor of submacular hemorrhage during anti-VEGF therapy
    Carlos Alexandre de Amorim Garcia Filho
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Ophthalmic Surg Lasers Imaging Retina 44:204-7. 2013
    ..Although further studies are needed, the increase in the volume of a PED may serve as a useful predictor of disease progression and the need for more aggressive anti-VEGF therapy...
  41. ncbi request reprint Verteporfin photodynamic therapy of choroidal neovascularization secondary to ocular toxoplasmosis
    Robert Wirthlin
    Bascom Palmer Eye Institute, 900 NW 17th Street, Miami, FL 33101, USA
    Arch Ophthalmol 124:741-3. 2006
  42. doi request reprint Strategies for following dry age-related macular degeneration
    Zohar Yehoshua
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Fla 33136, USA
    Ophthalmic Res 48:6-10. 2012
    ....
  43. pmc Automatic montage of SD-OCT data sets
    Ying Li
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Opt Express 19:26239-48. 2011
    ..The results for 3 normal eyes and 3 eyes with retinal degeneration are analyzed, showing registration errors of 1.5±0.3 and 2.0±0.8 pixels respectively...
  44. doi request reprint Avastin doesn't blind people, people blind people
    Serafin Gonzalez
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Am J Ophthalmol 153:196-203.e1. 2012
    ..To review the appropriate preparation of bevacizumab for intravitreal injection by compounding pharmacies with specific recommendations designed to prevent microbial contamination...
  45. ncbi request reprint Calibration of fundus images using spectral domain optical coherence tomography
    Brandon J Lujan
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Ophthalmic Surg Lasers Imaging 39:S15-20. 2008
    ..However, calibrated spectral domain OCT (SD-OCT) could offer a convenient alternative method for the calibration of any fundus image...
  46. doi request reprint Spectral domain optical coherence tomography imaging of dry age-related macular degeneration
    Zohar Yehoshua
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 NW 17th St, Miami, FL 33136, USA
    Ophthalmic Surg Lasers Imaging 41:S6-S14. 2010
    ..This unique feature of spectral domain optical coherence tomography makes it the ideal imaging modality for clinical trials designed to assess new drugs for the treatment of dry AMD...
  47. ncbi request reprint Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema
    Ingrid U Scott
    Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida 33101, USA
    Am J Ophthalmol 136:737-9. 2003
    ..To report intravitreal triamcinolone acetonide for idiopathic cystoid macular edema (ICME)...
  48. ncbi request reprint Geometric deformable model driven by CoCRFs: application to optical coherence tomography
    Gabriel Tsechpenakis
    Dept of Electrical and Computer Engineering, University of Miami, USA
    Med Image Comput Comput Assist Interv 11:883-91. 2008
    ..We apply our method to Optical Coherence Tomography fundus images for the segmentation of geographic atrophies in dry age-related macular degeneration of the human eye...
  49. doi request reprint Novel method for analyzing snellen visual acuity measurements
    Ninel Z Gregori
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Retina 30:1046-50. 2010
    ..A more intuitive approach is presented here which uses the conversion of Snellen visual acuity fractions to Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores for statistical manipulations...
  50. ncbi request reprint Pseudocystic foveal cavitation in tamoxifen retinopathy
    Rishi R Doshi
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
    Am J Ophthalmol 157:1291-1298.e3. 2014
    ..To present 3 cases of tamoxifen-induced foveal cavitation and review previous prospective and cross-sectional studies...
  51. doi request reprint Current Clinical Trials in Dry AMD and the Definition of Appropriate Clinical Outcome Measures
    Zohar Yehoshua
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Semin Ophthalmol 26:167-80. 2011
    ..Studies have identified genetic predispositions for dry AMD associated with complement dysfunction. Consequently, complement-based therapeutic treatment modalities are promising...
  52. ncbi request reprint New treatments for age-related macular degeneration
    Philip J Rosenfeld
    Lancet 370:1479; author reply 1480. 2007
  53. ncbi request reprint Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5
    Mark S Blumenkranz
    Arch Ophthalmol 120:1307-14. 2002
    ..To report vision and safety outcomes from an extension of a 2-year investigation evaluating verteporfin photodynamic therapy in patients with age-related macular degeneration with subfoveal choroidal neovascularization (CNV)...
  54. ncbi request reprint Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1
    Keven J Blinder
    Am J Ophthalmol 136:407-18. 2003
    ....
  55. ncbi request reprint Verteporfin therapy for CNV secondary to OHS
    David A Saperstein
    Ophthalmology 113:2371.e1-3. 2006
  56. ncbi request reprint Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3
    Jennifer J Arnold
    Am J Ophthalmol 137:683-96. 2004
    ....
  57. ncbi request reprint Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Vert
    Mohammad Azab
    Retina 24:1-12. 2004
    ....
  58. ncbi request reprint Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial
    Mohammad Azab
    Arch Ophthalmol 123:448-57. 2005
    ....
  59. ncbi request reprint Verteporfin in Photodynamic Therapy: report no. 5
    Francesco Bandello
    Ophthalmology 111:2144. 2004
  60. ncbi request reprint Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7
    Neil M Bressler
    Arch Ophthalmol 123:1283-5. 2005
  61. ncbi request reprint Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series
    David A Saperstein
    Ophthalmology 109:1499-505. 2002
    ..To evaluate the safety and effect on visual acuity of photodynamic therapy with verteporfin (Visudyne, Novartis AG) in patients with subfoveal choroidal neovascularization (CNV) secondary to the ocular histoplasmosis syndrome (OHS)...
  62. ncbi request reprint Promising new treatments for neovascular age-related macular degeneration
    Stephan Michels
    Klinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Wahringer Gurtel 18 20, Allgemeines Krankenhaus 8i, 1090 Wien Vienna, Austria
    Expert Opin Investig Drugs 15:779-93. 2006
    ..This review provides an overview on angiogenic mechanisms, potential antiangiogenic treatment strategies and different antiangiogenic drugs with special focus on neovascular AMD...
  63. ncbi request reprint Intravitreal avastin: the low cost alternative to lucentis?
    Philip J Rosenfeld
    Am J Ophthalmol 142:141-3. 2006
  64. ncbi request reprint An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration
    Anne E Fung
    Pacific Eye Associates, California Pacific Medical Center, San Francisco, California, USA
    Am J Ophthalmol 143:566-83. 2007
    ..To evaluate an optical coherence tomography (OCT)-guided, variable-dosing regimen with intravitreal ranibizumab for the treatment of patients with neovascular age-related macular degeneration (AMD)...
  65. ncbi request reprint Medical consequences of stopping anticoagulant therapy before intraocular surgery or intravitreal injections
    Steve Charles
    Retina 27:813-5. 2007
  66. ncbi request reprint Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study
    Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts 02114, USA
    Ophthalmology 113:633.e1-4. 2006
    ..To assess safety of repeated intravitreal injections of ranibizumab in treating neovascular age-related macular degeneration (AMD), and to assess changes in visual acuity (VA) and AMD lesion characteristics...
  67. pmc Age-related maculopathy: a genomewide scan with continued evidence of susceptibility loci within the 1q31, 10q26, and 17q25 regions
    Daniel E Weeks
    Department of Human Genetics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
    Am J Hum Genet 75:174-89. 2004
    ..The OSAs generate the interesting hypothesis that the effect of smoking on the risk of ARM is accentuated by a gene in the 10q26 region--a region implicated by four other studies...